GlycoMimetics Initiates First Clinical Trial of GMI-1271 as Potential Treatment for Blood-Related Cancers

June 19 2014: GlycoMimetics, Inc.announced today that the first healthy volunteer has been dosed in a Phase 1 clinical study designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271, a novel and proprietary E-selectin antagonist in the company’s pipeline. GlycoMimetics is initially exploring the clinical use of the drug candidate to treat acute myeloid leukemia (AML) following preclinical studies of GMI-1271 for blood cancers …

Trovagene Announces Clinical Collaboration with Dana-Farber Cancer Institute

June 16, 2014: Trovagene, Inc. (NASDAQ:   TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients. Under the agreement, urine samples will be collected from patients with locally …

Hunterdon Regional Cancer Center: The Only Cancer Center in New Jersey to Offer Immuno-Therapy Clinical Trial for Lung Cancer

June 11 2014: According to the American Cancer Society, lung cancer is the second most common cancer among men and women and the leading cause of death in the United States. In 2014, it is estimated that 224,210 people will be diagnosed with lung cancer. Hunterdon Regional Cancer Center was selected as the only cancer facility in New Jersey to offer a clinical …

5 things you should know about cancer patients

It’s not something I really talk about, but a recent conversation with a colleague convinced me that I should. Three years ago, I woke up from what was supposed to be the routine removal of a benign tumour in my left cheek to find out that in fact it was not benign but malignant. In the process of removing the …